Abstract:Guru Subramanian Guru Murthy Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA Correspondence: Guru Subramanian Guru Murthy, Division of Hematology & Oncology, Medical College of Wisconsin, Milwaukee, WI, USA, Tel +1 414-805-4600, Fax +1 414-805-6815, Email The management of chronic myeloid leukemia (CML) has remarkably changed in the last 20 years with the availability of tyrosine kinase inhibitors (TKI). Most patients with chronic phase CML now have a life expectancy like that of age matched controls. Understanding the practical aspects of choosing the appropriate TKI, monitoring response and side-effects are key to long term success. Currently, treatment cessation is also an option in patients achieving sustained deep molecular response. Novel agents are needed in patients with lack of response to TKI and in those with advanced disease. Keywords: leukemia, myeloid, chronic, treatment Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of t (9, 22) leading to BCR-ABL1 gene rearrangement. In United States, it is diagnosed at a median age of 67 years with about 8450 new cases in 2020. 1 Although CML was considered as a deadly disease in the past, the availability of BCR-ABL tyrosine kinase inhibitors (TKI) have remarkably changed the outlook of this disease. Currently, CML is considered as a disease that is well manageable with oral TKI giving excellent long-term results and the option for stopping treatment in some patients. In this review, we will discuss about the practical aspects of managing CML and the common considerations given at various levels of management. Most patients with CML present with leukocytosis and left shifted granulocytes, and/or thrombocytosis. Symptoms at presentation are variable and could include fever, night sweats, fatigue, and some patients are asymptomatic. To diagnose CML, the demonstration of the Philadelphia chromosome abnormality or the BCR-ABL gene rearrangement is important. At the cytogenetic level, CML is characterized by a reciprocal translocation in chromosomes 9 and 22. 2 This leads to the fusion of BCR and ABL1 genes. The breakpoint typically occurs in introns 13 or 14 of the BCR gene in chromosome 22 and exons 1 or 2 of ABL1 in chromosome 9. This results in the typical transcripts (e13a2 or e14a2) and major fusion protein (p210). In some patients, the break points can occur at other exon location (e1a2 with p190, e19a2 with p230, e13a3, e14a3) and should be considered if the classical major BCR is not present. Confirmation of t (9, 22) can be done using conventional karyotyping or Fluorescence-in-situ-hybridization studies and the identification and quantitation of the BCR-ABL1 fusion transcripts can be done using polymerase chain reaction (PCR). Testing can be done either from the peripheral blood or bone marrow specimens, although, obtaining a bone marrow biopsy at baseline would also assist in confirming the disease phase and provide an opportunity to assess for additional chromosomal abnormalities. Once a diagnosis established, it is important to know the disease phase and the risk status to determine the optimal first line therapy. CML has 3 phases - chronic, accelerated and blast phase. While most of the patients diagnosed with CML are in chronic phase, some patients have higher disease risk with presentations such as accelerated or blast phase. Knowing the disease phase is important as the management and prognosis differs significantly based on this aspect. Patients with chronic phase CML now have a survival that is similar to age matched controls without CML, but patients with blast phase CML have a median survival of 7–11 months. 3,4 Chronic phase CML can be risk stratified using Sokal risk score (used more commonly in US) based on age, spleen size by clinical exam, platelet counts and peripheral blast percentage. 5 This stratification helps in understanding the prognosis and choosing the first line therapy. Currently, imatinib, dasatinib, nilotinib and bosutinib are available as first line options for management of CML. Imatinib is a first generation TKI that was compared against interferon and cytarabine for newly diagnosed CML and showed significantly higher response rates (major cytogenetic response 87.1% vs 34.1%) and lower risk of transformation to accelerated or blast phase (freedom from progression 96.7% vs 91.5%). 6 Subsequently, second generation TKI such as dasatinib, nilotinib, and bosutinib were compared against imatinib in prospective clinical studies and showed encouraging efficacy 7–12 (Table 1). In general, starting treatment with second generation TKI would lead to quicker achievement of cytogenetic and molecular responses, minimizes the risk of transformation to accelerated phase or bl -Abstract Truncated-

Diagnosis and first-line treatment of newly diagnosed chronic myeloid leukemia

The Treatment of Patients with Chronic Myeloid Leukemia Chronic Phase Combined with Myelofibrosis with Tyrosine Kinase Inhibitors: A Chinese Population-Based Study.

P684: a multicenter retrospective study in china: clinical characteristics and prognosis of patients with cml-cp treated with different tyrosine kinase inhibitors

How I Manage Patients with Chronic Myeloid Leukemia (CML): Perspectives from Clinical Practice

Early BCR-ABL1 Decline in Imatinib-Treated Patients with Chronic Myeloid Leukemia: Results from a Multicenter Study of the Chinese CML Alliance

Treatment and diagnosis progress of chronic myeloid leukemia

Treatment Status of Tyrosine Kinase Inhibitor for Newly-Diagnosed Chronic Myeloid Leukemia: a Domestic Multi-Centre Retrospective Real-World Study

Control of Ph+ and additional chromosomal abnormalities in chronic myeloid leukemia by tyrosine kinase inhibitors

Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring

Treatment Status of Tyrosine Kinase Inhibitors in Chinese Patients with Chronic Myeloid Leukemia in 2020

Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring

Chronic myeloid leukemia: the paradigm of targeting oncogenic tyrosine kinase signaling and counteracting resistance for successful cancer therapy

Comparative efficacy and safety of first-line tyrosine kinase inhibitors in chronic myeloid leukemia: a systematic review and network meta-analysis

Comparison of the Outcome Between Newly Diagnosed Patients in the Accelerated Phase and Chronic Phase with Chronic Myeloid Leukemia Treated with Frontline Tyrosine Kinase Inhibitors

Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies

Pathogenesis and management of accelerated and blast phases of chronic myeloid leukemia

Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure

Clinical Practice Guideline for Chronic Myelogenous Leukemia and Its Practice in China

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings

Detection of FLT3/ITD, JAK2(V617F) and NPM1 gene mutations in chronic myelomonocytic leukemia

Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology